|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current and future treatments for hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) represents a unique challenge for physicians and patients.There is no definitively curative treatment.Rather,many treatment and management modalities exist with differing advantages and disadvantages.Both current guidelines and individual patient concerns must be taken into account in order to properly manage HCC.In addition,quality of life issues are particularly complex in patients with HCC and these concerns must also be factored into treatment strategies.Thus,considering all the options and their various pros and cons can quickly become complex for both clinicians and patients.In this review,we systematically discuss the current treatment modalities available for HCC,detailing relevant clinical data,risks and rewards and overall outcomes for each approach.Surgical options discussed include resection,transplantation and ablation.We also discuss the radiation modalities:conformal radiotherapy,yttrium 90 microspheres and proton and heavy ion radiotherapy.The biologic agent Sorafenib is discussed as a promising new approach,and recent clinical trials are reviewed.We then detail currently described molecular pathways implicated in the initiation and progression of HCC,and we explore the potential of each pathway as an avenue for drug exploitation.We hope this comprehensive and forward-looking review enables both clinicians and patients to understand various options and thereby make more informed decisions regarding this disease. | Alexander Schlachterman Willie W Craft Jr Eric Hilgenfeldt Avir Mitra Roniel Cabrera | 2015 | World Journal of Gastroenterology2015，21，28： | 76 |
| 2 | Disease monitoring of hepatocellular carcinoma through metabolomics显示文摘We elucidate major pathways of hepatocarcinogenesis and accurate diagnostic metabolomic biomarkers of hepatocellular carcinoma(HCC) identified by contemporary HCC metabolomics studies, and delineate a model HCC metabolomics study design. A literature search was carried out on Pubmed for HCC metabolomics articles published in English. All relevant articles were accessed in full text. Major search terms included 'HCC', 'metabolomics', 'metabolomics', 'metabonomic' and 'biomarkers'. We extracted clinical and demographic data on all patients and consolidated the lead candidate biomarkers, pathways, and diagnostic performance of metabolomic expression patterns reported by all studies in tables. Where reported, we also extracted and summarized the metabolites and pathways most highly associated with the development of cirrhosis in table format. Pathways of lysophospholipid, sphingolipid, bile acid, amino acid, and reactive oxygen species metabolism were most consistently associated with HCC in the cited works. Several studies also elucidate metabolic alterations strongly associated with cirrhosis, with γ-glutamyl peptides, bile acids, and dicarboxylic acids exhibiting the highest capacity for stratifying cirrhosis patients from appropriately matched controls. Collectively, global metabolomic profiles of the referenced works exhibit a promising diagnostic capacity for HCC at a capacity greater than that of conventional diagnostic biomarker alpha-fetoprotein. Metabolomics is a powerful strategy for identifying global metabolic signatures that exhibit potential to be leveraged toward the screening, diagnosis, and management of HCC. A streamlined study design and patient matching methodology may improve concordance among metabolomic datasets in future works. | Asem I Fitian Roniel Cabrera | 2017 | World Journal of Hepatology2017，9，1： | 5 |
| 3 | Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma显示文摘 | Roniel Cabrera Miguel Ararat Yiling Xu Todd Brusko Clive Wasserfall Mark A. Atkinson Lung Ji Chang Chen Liu David R. Nelson | 2013 | Cancer Immunology Immunotherapy2013，，4： | 3 |
| 4 | Advances in the management of cholangiocarcinoma显示文摘Cholangiocarcinoma(CCA)is a primary malignancy of the bile ducts with three anatomically and molecularly distinct entities:Intrahepatic CCA(iCCA),perihilar CCA(pCCA),and distal CCA.As a result of phenotypic and anatomic differences they differ significantly with respect to management.For each type of CCA there have been significant changes in management over the last several years which will be discussed in this review.Although resection remains the standard of care for all types of CCA,liver transplantation has been established as curative treatment for selected patients with pCCA and is being evaluated for iCCA with early success.With respect to systemic therapy capecitabine is now first line adjuvant therapy for all biliary tract malignancies after curative intent resection.Progress in exploiting the pathologic mutations and molecular abnormalities has also yielded regulatory approval of targeted therapy for CCA in patients with acquired alterations in the fibroblast growth factor receptor.There is also increased consensus in managing malignant biliary obstruction associated with CCA where pre-operative biliary stenting is not beneficial while self-expanding metal stents have been shown to be superior to plastic stents in patients who are not surgical candidates. | Andreas G Zori Dennis Yang Peter V Draganov Roniel Cabrera | 2021 | World Journal of Hepatology2021，13，9： | 2 |
| 5 | Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma显示文摘 | Renumathy Dhanasekaran Alan Hemming Ivan Zendejas Thomas George David Nelson Consuelo Soldevila-Pico Roberto Firpi Giuseppe Morelli Virginia Clark Roniel Cabrera | 2013 | Oncology Reports2013，，4： | 1 |
| 6 | Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma显示文摘 | Roniel Cabrera Miguel Ararat Yiling Xu Todd Brusko Clive Wasserfall Mark A. Atkinson Lung Ji Chang Chen Liu David R. Nelson | 2013 | Cancer Immunology, Immunotherapy2013，，： | 1 |
| 7 | An immunomodulatory role for CD4^+CD25^+ regulatory T lymphocytes in Hepatitis C virus infection显示文摘 | Roniel Cabrera Zhengkun Tu Yiling Xu | 2004 | Hepatology2004，405，： | 1 |
| 8 | The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: A Randomized Pilot Study显示文摘 | Roberto J. Firpi Consuelo Soldevila-Pico Giuseppe G. Morelli Roniel Cabrera Cynthia Levy Virginia C. Clark Amitabh Suman Anthony Michaels Chaoru Chen David R. Nelson | 2010 | Digestive Diseases and Sciences2010，，1： | 1 |
| 9 | The Use of Cyclosporine for Recurrent Hepatitis C After Liver Transplant: A Randomized Pilot Study显示文摘 | Roberto J. Firpi Consuelo Soldevila-Pico Giuseppe G. Morelli Roniel Cabrera Cynthia Levy Virginia C. Clark Amitabh Suman Anthony Michaels Chaoru Chen David R. Nelson | 2010 | Digestive Diseases and Sciences2010，，1： | 1 |
| 10 | Serum levels of soluble CD25 as a marker for hepatocellular carcinoma显示文摘 | Roniel Cabrera Asem Fitian Miguel Ararat Yiling Xu Todd Brusko Clive Wasserfall Mark Atkinson Chen Liu David Nelson | 2012 | Oncology Letters2012，，4： | 1 |
| 11 | Neutrophil–lymphocyte ratio predicts overall and recurrence‐free survival after liver transplantation for hepatocellular carcinoma显示文摘 | Alpna R. Limaye Virginia Clark Consuelo Soldevila‐Pico Giuseppe Morelli Amitabh Suman Roberto Firpi David R. Nelson Roniel Cabrera | 2013 | Hepatol Res2013，，7： | 1 |
| 12 | CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant显示文摘 | Roberto J. Firpi Huijia Dong Virginia C. Clark Consuelo Soldevila‐Pico Giuseppe Morelli Roniel Cabrera Oxana Norkina Jonathan J. Shuster David R. Nelson Chen Liu | 2012 | Liver Int2012，，1： | 1 |
| 13 | Adherence to guideline-directed hepatocellular carcinoma screening:A single-center US experience显示文摘BACKGROUND The American Association for the Study of Liver Disease recommends screening patients with cirrhosis for hepatocellular carcinoma(HCC)using imaging with or without alpha-fetoprotein every six months.Unfortunately,screening rates remain inadequate.AIM To assess root causes of screening failure in a subspecialty hepatology clinic.METHODS The authors identified patients with cirrhosis seen in a subspecialty hepatology clinic and determined whether they underwent appropriate screening,defined as two cross-sectional images between five and seven months apart.The authors characterized the primary driver of screening failure.Finally,other hepatologists were surveyed to determine provider perceptions of screening failure causes.RESULTS 1034 patients were identified with an average age of 61 years and a mean MELD of 8.1±3.8.Hepatitis C virus was the most common cirrhosis etiology.489(47%)underwent appropriate screening.No demographic or clinical differences were detected between those who underwent appropriate screening and those who did not.The most common etiologies of screening failure,in descending order,were:radiology unable to schedule timely imaging,provider did not order imaging,patient canceled follow up appointment,appointments scheduled too far apart,lost to follow up,no-show to radiology appointment,and provider canceled appointment.Hepatologists surveyed believed the most common cause of screening failure was no-show to radiology.CONCLUSION Rates of screening were poor even in a subspecialty hepatology clinic.Screening failure was mostly due to systemic factors such as radiology availability and time between hepatology appointments rather than individual error. | William W King Raymond Richhart Tyler Culpepper Maneola Mota Debdeep Banerjee Media Ismael Joydeep Chakraborty Michael Ladna Walid Khan Nicole Ruiz Jake Wilson Ellery Altshuler Virginia Clark Roniel Cabrera | 2023 | World Journal of Hepatology2023，15，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员